Valued at USD 5.60 billion in 2024, the global neurology clinical trials market is projected to reach USD 5.96 billion in 2025 and USD 10.59 billion by 2034, growing at a CAGR of 6.6% during the forecast period 2025–2034. The increasing prevalence of neurological diseases such as Alzheimer's disease and Parkinson's disease drives demand, along with a growing need for new and effective treatments and rising research and development funding from public and private sources. This article reviews the main drivers, segment leaders, and regional picture for B2B sponsors, CROs, and investigators.

Rising Disease Burden

The number of people suffering from neurological disorders is increasing significantly around the world. As the global population ages, conditions such as Alzheimer's disease, Parkinson's disease, and stroke are becoming more common, creating a greater need for new treatments. These diseases often lead to disability and a lower quality of life, which gives pharmaceutical and biotechnology companies a strong incentive to invest in research and development.

The report also points to growing global burden from epilepsy and multiple sclerosis, and to increased funding in precision medicine, gene therapies, and treatments targeting neuroinflammation as new research directions.

Government Funding and Support

Increasing government funding is a major driver. Governments and public health organizations are raising funding for neurology research through grants, partnerships, and special programs designed to speed the discovery and development of treatments. This support reduces risk for companies and research institutions, making it easier to start and run complex trials. The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, actively funds a wide range of clinical research studies. Public initiatives often focus on diseases that have a big impact on society and few effective treatments, and targeted government funding helps researchers tackle some of the most difficult conditions.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/neurology-clinical-trials-market

Segment Leaders

By phase, the phase III segment held the largest share in 2024 because these trials are the most extensive and expensive part of drug development. They involve large groups of patients and confirm the effectiveness and safety of a treatment before it can be approved. By study design, interventional studies held the largest share, since they are the most common type used for testing new drugs and medical devices; participants receive a specific treatment according to a research protocol, allowing researchers to directly measure effects.

By indication, Alzheimer's disease held the largest share in 2024 because of the significant global burden and the lack of effective long-term treatments. By value chain, the in-house segment held the largest share as many large pharmaceutical and biotechnology companies manage trials from start to finish with their own resources and expertise.

Regional Analysis

North America accounted for the largest share in 2024 because of its advanced healthcare infrastructure and a high concentration of major pharmaceutical and biotechnology companies. The U.S. is the primary contributor, with top-tier academic research centers, a strong network of clinical research sites, and a high number of ongoing trials for conditions such as Alzheimer's and Parkinson's disease.

Europe represents a significant part of the market, with Germany a major contributor, though some industry reports indicate a slight loss of its global share to emerging regions. Asia Pacific is growing rapidly on its large and diverse patient population, with China streamlining trial approvals.

Competitive Landscape

Key players neurology clinical trials include Biogen, Charles River Laboratories, Eisai Co., Ltd., ICON plc, IQVIA, Laboratory Corporation of America Holdings, Medpace Holdings, Inc., Parexel, Pfizer Inc., Syneos Health, and Thermo Fisher Scientific. Competition revolves around expertise in complex neurological conditions, technological capabilities for data management and patient recruitment, and global trial capability. In February 2025, Thermo Fisher launched a clinical registry and biorepository for Systemic Lupus Erythematosus through its CorEvitas business. High trial failure rates due to complexity remain a challenge.

More Trending Latest Reports By Polaris Market Research:

laundry-detergent-market

outsourced-semiconductor-assembly-and-test-market

global-paints-and-coatings-market

radiotheranostics-market

glp-1-analogues-market

multiparameter-patient-monitoring-market

vanillin-market

warehouse-automation-market

alginate-market